Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.

Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, Zhang Y, Li Z, Tam BT, Lin P, Xiao M, Young KH, Amini B, Starbuck MW, Lee HC, Navone NM, Davis RE, Tong Q, Bergsagel PL, Hou J, Yi Q, Orlowski RZ, Gagel RF, Yang J.

Sci Transl Med. 2019 May 29;11(494). pii: eaau9087. doi: 10.1126/scitranslmed.aau9087.

PMID:
31142679
2.

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).

Bethel MA, Patel RA, Thompson VP, Merrill P, Reed SD, Li Y, Ahmadi S, Katona BG, Gustavson SM, Ohman P, Iqbal N, Gagel RF, Hernandez AF, Buse JB, Holman RR; EXSCEL Study Group.

Diabetes Care. 2019 Jun;42(6):1075-1080. doi: 10.2337/dc18-2028. Epub 2019 Apr 22.

PMID:
31010875
3.

Tumor-induced hypophosphatemic osteomalacia caused by a mesenchymal tumor of the mandible managed by a segmental mandibulectomy and microvascular reconstruction with a free fibula flap.

Acharya RP, Won AM, Moon BS, Flint JH, Roubaud MS, Williams MD, Hessel AC, Murphy WA Jr, Chambers MS, Gagel RF.

Head Neck. 2019 Jun;41(6):E93-E98. doi: 10.1002/hed.25657. Epub 2019 Mar 11.

PMID:
30859653
4.

Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.

Sinha KM, Bagheri-Yarmand R, Lahiri S, Lu Y, Zhang M, Amra S, Rizvi Y, Wan X, Navone N, Ozpolat B, Logothetis C, Gagel RF, Huard J.

Oncogene. 2019 Jun;38(25):5038-5049. doi: 10.1038/s41388-019-0774-x. Epub 2019 Mar 11.

PMID:
30858546
5.

Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.

Hu MI, Elisei R, Dedecjus M, Popovtzer A, Druce M, Kapiteijn E, Pacini F, Locati L, Krajewska J, Weiss R, Gagel RF.

Endocr Relat Cancer. 2019 Feb 1;26(2):241-250. doi: 10.1530/ERC-18-0258.

PMID:
30557850
6.

Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer.

Bagheri-Yarmand R, Sinha KM, Li L, Lu Y, Cote GJ, Sherman SI, Gagel RF.

Mol Cancer Res. 2019 Mar;17(3):751-760. doi: 10.1158/1541-7786.MCR-18-0354. Epub 2018 Dec 14.

PMID:
30552230
7.

Correction to: Hip fracture trends in the United States, 2002 to 2015.

Lewiecki EM, Wright NC, Curtis JR, Siris E, Gagel RF, Saag KG, Singer AJ, Steven PM, Adler RA.

Osteoporos Int. 2018 Nov;29(11):2583. doi: 10.1007/s00198-018-4685-4.

PMID:
30151621
8.

Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma.

Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL Jr, Waguespack SG, Perrier ND, Grubbs EG.

Ann Surg Oncol. 2018 May;25(5):1395-1402. doi: 10.1245/s10434-018-6366-0. Epub 2018 Feb 9.

PMID:
29427212
9.

Hip fracture trends in the United States, 2002 to 2015.

Lewiecki EM, Wright NC, Curtis JR, Siris E, Gagel RF, Saag KG, Singer AJ, Steven PM, Adler RA.

Osteoporos Int. 2018 Mar;29(3):717-722. doi: 10.1007/s00198-017-4345-0. Epub 2017 Dec 27. Erratum in: Osteoporos Int. 2018 Aug 27;:.

PMID:
29282482
10.

Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.

Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA Jr.

Support Care Cancer. 2018 May;26(5):1561-1568. doi: 10.1007/s00520-017-3962-7. Epub 2017 Dec 2.

PMID:
29197959
11.

Differential effects of Calca-derived peptides in male mice with diet-induced obesity.

Bartelt A, Jeschke A, Müller B, Gaziano I, Morales M, Yorgan T, Heckt T, Heine M, Gagel RF, Emeson RB, Amling M, Niemeier A, Heeren J, Schinke T, Keller J.

PLoS One. 2017 Jun 30;12(6):e0180547. doi: 10.1371/journal.pone.0180547. eCollection 2017.

12.

Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.

Voss RK, Feng L, Lee JE, Perrier ND, Graham PH, Hyde SM, Nieves-Munoz F, Cabanillas ME, Waguespack SG, Cote GJ, Gagel RF, Grubbs EG.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2807-2813. doi: 10.1210/jc.2017-00317.

13.

Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial.

Lu H, Champlin RE, Popat U, Pundole X, Escalante CP, Wang X, Qiao W, Murphy WA, Gagel RF.

Bonekey Rep. 2016 Oct 19;5:843. doi: 10.1038/bonekey.2016.72. eCollection 2016.

14.

ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.

Bagheri-Yarmand R, Williams MD, Grubbs EG, Gagel RF.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):933-941. doi: 10.1210/jc.2016-2878.

15.

Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.

Grubbs EG, Williams MD, Scheet P, Vattathil S, Perrier ND, Lee JE, Gagel RF, Hai T, Feng L, Cabanillas ME, Cote GJ.

Thyroid. 2016 Nov;26(11):1553-1562. Epub 2016 Oct 18.

16.

Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation.

Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ.

Thyroid. 2016 Dec;26(12):1744-1751. Epub 2016 Oct 18.

17.

Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.

Xu JY, Murphy WA Jr, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI.

J Clin Endocrinol Metab. 2016 Dec;101(12):4871-4877. Epub 2016 Sep 23.

18.

Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.

Liu H, Liu Z, Du J, He J, Lin P, Amini B, Starbuck MW, Novane N, Shah JJ, Davis RE, Hou J, Gagel RF, Yang J.

Sci Transl Med. 2016 Aug 24;8(353):353ra113. doi: 10.1126/scitranslmed.aad8949.

19.

Changing of the Guard.

Wierman ME, Chin WW, Clemmons DR, Gagel RF, Larsen JL.

Endocr Rev. 2016 Feb;2016(1):1-2. doi: 10.1210/EDRV-ER.2015-1072.2016.1.test. No abstract available.

PMID:
27454359
20.

The National Osteoporosis Foundation's methods and processes for developing position statements.

Wallace TC, Bauer DC, Gagel RF, Greenspan SL, Lappe JM, LeBoff MS, Recker RR, Saag KG, Singer AJ.

Arch Osteoporos. 2016;11:22. doi: 10.1007/s11657-016-0276-1. Epub 2016 May 26.

PMID:
27229335
21.

Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.

Dadu R, Hu MN, Grubbs EG, Gagel RF.

Recent Results Cancer Res. 2015;204:227-49. doi: 10.1007/978-3-319-22542-5_11. Review.

PMID:
26494392
22.

Changing of the Guard.

Wierman ME, Chin WW, Clemmons DR, Gagel RF, Larsen JL.

Endocr Rev. 2015 Aug;36(4):345-6. doi: 10.1210/EDRV-ER.2015-1072. No abstract available.

PMID:
26240982
23.

Treatment of osteoporosis is not futile.

Lee DB, Adler RA, Gagel RF.

BMJ. 2015 Jul 14;351:h3274. doi: 10.1136/bmj.h3274. No abstract available.

PMID:
26174815
24.

My, How Things Have Changed in Multiple Endocrine Neoplasia Type 2A!

Grubbs EG, Gagel RF.

J Clin Endocrinol Metab. 2015 Jul;100(7):2532-5. doi: 10.1210/jc.2015-2516. No abstract available.

25.

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma.

Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335. Review.

26.

A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis.

Bagheri-Yarmand R, Sinha KM, Gururaj AE, Ahmed Z, Rizvi YQ, Huang SC, Ladbury JE, Bogler O, Williams MD, Cote GJ, Gagel RF.

J Biol Chem. 2015 May 1;290(18):11749-61. doi: 10.1074/jbc.M114.619833. Epub 2015 Mar 20.

27.

Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E.

Thyroid. 2014 Jul;24(7):1096-106. doi: 10.1089/thy.2013.0620. Epub 2014 Jun 6.

28.

A miRNA signature associated with human metastatic medullary thyroid carcinoma.

Santarpia L, Calin GA, Adam L, Ye L, Fusco A, Giunti S, Thaller C, Paladini L, Zhang X, Jimenez C, Trimarchi F, El-Naggar AK, Gagel RF.

Endocr Relat Cancer. 2013 Oct 14;20(6):809-23. doi: 10.1530/ERC-13-0357. Print 2013 Dec.

PMID:
24127332
29.

The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.

Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA, Jimenez C.

J Clin Endocrinol Metab. 2013 Nov;98(11):E1813-9. doi: 10.1210/jc.2013-1653. Epub 2013 Sep 12.

30.

NCCN Task Force Report: Bone Health In Cancer Care.

Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S, Van Poznak CH.

J Natl Compr Canc Netw. 2013 Aug;11 Suppl 3:S1-50; quiz S51. Review.

PMID:
23997241
31.

Diabetes and cancer--an AACE/ACE consensus statement.

Handelsman Y, Leroith D, Bloomgarden ZT, Dagogo-Jack S, Einhorn D, Garber AJ, Grunberger G, Harrell RM, Gagel RF, Lebovitz HE, McGill JB, Hennekens CH.

Endocr Pract. 2013 Jul-Aug;19(4):675-93. doi: 10.4158/EP13248.CS. No abstract available. Erratum in: Endocr Pract. 2013 Sep-Oct;19(5):899.

PMID:
23978590
32.

Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile.

Jain P, Baez-Vallecillo L, Huh YO, Benjamini O, Abruzzo L, O'Brien S, Pemmaraju N, Keating M, Gagel RF, Estrov Z.

Leuk Lymphoma. 2014 Apr;55(4):944-6. doi: 10.3109/10428194.2013.813666. Epub 2014 Jan 24. No abstract available.

33.

Deletion of the gene encoding calcitonin and calcitonin gene-related peptide α does not affect the outcome of severe infection in mice.

Tuvim MJ, Clement CG, Huang ES, Cote GJ, Evans SE, Lei X, Deftos LJ, Gagel RF, Dickey BF.

Am J Respir Cell Mol Biol. 2013 Jul;49(1):151-5. doi: 10.1165/rcmb.2012-0489OC.

34.
35.

The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.

Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL.

J Clin Endocrinol Metab. 2013 Jan;98(1):31-42. doi: 10.1210/jc.2012-2909. Epub 2012 Nov 26. Review.

36.

Activation of G-protein-coupled receptors and thyroid malignant tumors: the jury is still out.

Gagel RF.

Endocr Pract. 2011 Nov-Dec;17(6):957-9. No abstract available.

PMID:
22193147
37.

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ.

J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24. Erratum in: J Clin Oncol. 2013 Aug 20;31(24):3049.

38.

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R.

J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23.

39.

Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly.

Jimenez C, Ayala-Ramirez M, Liu J, Nunez R, Gagel RF.

Horm Metab Res. 2011 Jan;43(1):55-61. doi: 10.1055/s-0030-1268006. Epub 2010 Nov 22.

PMID:
21104581
40.

Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.

Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF.

Ann N Y Acad Sci. 2011 Feb;1218:47-54. doi: 10.1111/j.1749-6632.2010.05771.x. Epub 2010 Sep 28. Review.

PMID:
20946574
41.

The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.

Ye L, Santarpia L, Gagel RF.

Endocr Rev. 2010 Aug;31(4):578-99. doi: 10.1210/er.2009-0031. Epub 2010 Jul 6. Review.

PMID:
20605972
42.

Cancer therapies and bone health.

Hu MI, Lu H, Gagel RF.

Curr Rheumatol Rep. 2010 Jun;12(3):177-85. doi: 10.1007/s11926-010-0098-x. Review.

PMID:
20437119
43.

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M.

J Clin Oncol. 2010 Feb 10;28(5):767-72. doi: 10.1200/JCO.2009.23.6604. Epub 2010 Jan 11.

44.

Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.

Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R.

Clin Cancer Res. 2009 Nov 15;15(22):7061-8. doi: 10.1158/1078-0432.CCR-09-1241. Epub 2009 Nov 10.

45.

NCCN Task Force Report: Bone Health in Cancer Care.

Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH.

J Natl Compr Canc Netw. 2009 Jun;7 Suppl 3:S1-32; quiz S33-5.

46.

The calcitonin/calcitonin gene related peptide-alpha gene is not required for 1alpha,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis.

Becklund BR, James BJ, Gagel RF, DeLuca HF.

Arch Biochem Biophys. 2009 Aug 15;488(2):105-8. doi: 10.1016/j.abb.2009.06.015. Epub 2009 Jun 27.

PMID:
19563774
47.

Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm.

Ye L, Santarpia L, Gagel RF.

Endocr Pract. 2009 Sep-Oct;15(6):597-604. doi: 10.4158/EP09148.RAR. Review.

PMID:
19546050
48.

Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.

Santarpia L, Ye L, Gagel RF.

J Intern Med. 2009 Jul;266(1):99-113. doi: 10.1111/j.1365-2796.2009.02112.x. Review.

49.

Medullary thyroid cancer: management guidelines of the American Thyroid Association.

American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr.

Thyroid. 2009 Jun;19(6):565-612. doi: 10.1089/thy.2008.0403. Review. Erratum in: Thyroid. 2009 Nov;19(11):1295.

PMID:
19469690

Supplemental Content

Loading ...
Support Center